<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00483184</url>
  </required_header>
  <id_info>
    <org_study_id>04HUBD01</org_study_id>
    <nct_id>NCT00483184</nct_id>
  </id_info>
  <brief_title>Low Dose Interferon Alpha Treatment for Oral Ulcers of Behcet's Disease</brief_title>
  <official_title>Phase II Study, Evaluation of Low Dose Natural Human Interferon Alpha Administered by the Oral Mucosal Route in the Treatment of Behçet's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nobel Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amarillo Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Nobel Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and efficacy of natural human interferon
      alpha (IFN alpha) on size, number, incidence and pain of oral ulcers associated with Behçet's
      Disease (BD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Behçet's disease is a severe chronic relapsing inflammatory disorder marked by oral and
      genital ulcers, uveitis and skin lesions, as well as varying multisystem involvement
      including the joints, blood vessels, central nervous system, and gastrointestinal tract. Oral
      ulcers are the initial symptom for most of Behçet's cases and are the single manifestation of
      the disease required for an official diagnosis, along with two other hallmark symptoms.

      Ninety (90) patients will be enrolled in a randomized, parallel, double-blind,
      placebo-controlled study to evaluate the effectiveness of low dose natural human IFN α
      administered by the oral mucosal route in reducing the number, size, incidence and pain of
      oral ulcers in patients with Behçet's disease.

      The clinical trial will consist of 3 groups of patients randomized in a 1:1:1 ratio to twice
      daily receive 2 lozenges containing 500 IU IFN α(2,000 IU daily, n=30), one active (500 IU)
      and one placebo lozenge (1,000 IU daily, n=30) or 2 placebo lozenges (n=30). Subjects will be
      monitored weekly over an initial 4 weeks of treatment and then bi-weekly over an additional 8
      weeks of treatment. Medication will be self-administered as 2 lozenges taken twice daily
      (morning and evening). Oral lesions will be counted and measured at each study visit, and
      patients will answer a series of questionnaires. Results will be subjected to statistical
      analysis at the completion of the study, with change in total ulcer burden of a patient, a
      measurement of the total oral mucosal surface area involved with ulcerous lesions at each
      visit, serving as the primary endpoint. The total ulcer burden from each treated visit will
      be compared to the baseline total ulcer burden and the amount of change determined. Patients
      with a 75% decrease in total ulcer burden will be considered responders.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of Patients Experiencing a Sustained Response for Each Treatment Arm.</measure>
    <time_frame>(0-12 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Initial Response, Oral Ulcer Sustained Response, Oral Ulcer Recurrence, Time to Recurrence, Pain Associated With Oral Lesions, General Well-Being, Safety</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Behcet Syndrome</condition>
  <condition>Behcet Disease</condition>
  <condition>Mucocutaneous Ulceration</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>(placebo)0 IU IFNa</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Veldona)500 IU IFNα bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Veldona)1000 IU IFNα bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Veldona,</intervention_name>
    <description>Very low dose oral natural human interferon alpha lozenges</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is a male or a non-pregnant, non-lactating female.

          -  Has a history and clinical presentation consistent with a diagnosis of Behçet's
             Disease and meets International Study Group criteria (Appendix B).

          -  Has a history of oral ulcers for at least 12 months.

          -  Has a history of monthly episodes of multiple oral ulcers.

          -  Has the presence of at least 2 oral ulcers at study entry, both of which are
             accessible to measurement, with a total diameter of at least 4 mm.

          -  Has signed an IRB approved subject consent form.

          -  Has completed all screening procedures satisfactorily, is deemed to be an acceptable
             subject and is otherwise eligible for entry into the study.

          -  Is willing and able to comply with the protocol.

        Exclusion Criteria:

          -  Has a severe, acute, or chronic systemic disease other than Behçet's Disease such as
             congestive heart failure, hepatic failure, renal failure, Systemic Lupus Erythematosus
             (SLE), Stevens-Johnson syndrome, ulcerative colitis, cancer, leukemia, diabetes, AIDS
             or ARC, or any other condition for which they are immunocompromised.

          -  Is under active treatment for dental conditions, such that multiple dental office
             visits would be required during the study period, or presents with oral conditions
             which are not thought to be related to Behçet's Disease and, in the judgment of a
             qualified dentist, will require treatment during the study period.

          -  Is suffering from any medical condition other than Behçet's Disease known to cause
             oral ulcerations, such as erosive lichen planus, benign mucous membrane pemphigoid,
             SLE, Crohn's disease, Reiter's syndrome, or AIDS.

          -  Has an eating disorder and/or psychiatric illness requiring treatment.

          -  Has hypersensitivity to interferon-alpha.

          -  Is a pregnant or lactating female, or is of childbearing potential and is not using a
             medically acceptable contraceptive method throughout the study.

          -  Has had previous exposure to any parenteral interferon therapy.

          -  Has had exposure to IFNα lozenges within 30 days of screening.

          -  Has had exposure to thalidomide within 30 days of screening.

          -  Has had exposure to methotrexate within 30 days of screening.

          -  Has had exposure to any immune-suppressive medication within 30 days of screening.

          -  Has a history of, or is currently exhibiting, any disease or condition which, in the
             opinion of the Principal Investigator, would place the subject at increased risk
             during study therapy.

          -  Has any abnormality in a hematological or biochemical variable which, in the opinion
             of the Principal Investigator, would place the subject at increased risk during study
             therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hasan Yazici, MD</last_name>
    <role>Study Director</role>
    <affiliation>Istanbul University Cerrahpaşa Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cem Mat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istanbul University Cerrahpasa Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cengiz Korkmaz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Osmangazi University Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ayhan Dinc, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gülhane Military Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ahmet Gul, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>İstanbul University Istanbul Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gulhane Military Medical School</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osmangazi University Medical School, Dept of Rheumatology</name>
      <address>
        <city>Eskisehir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul University Cerrahpasa Medical School Department of Internal Medicine</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul University Istanbul Medical School</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2007</study_first_submitted>
  <study_first_submitted_qc>June 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2007</study_first_posted>
  <results_first_submitted>April 27, 2009</results_first_submitted>
  <results_first_submitted_qc>April 27, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 16, 2009</results_first_posted>
  <last_update_submitted>April 27, 2009</last_update_submitted>
  <last_update_submitted_qc>April 27, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 16, 2009</last_update_posted>
  <responsible_party>
    <name_title>Hasan Zeytin</name_title>
    <organization>Nobel Pharmaceuticals</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Behcet Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Eighty four Behcet's Disease patients were followed at the rheumatology or dedicated BS outpatient clinics of 4 medical schools in Turkey.</recruitment_details>
      <pre_assignment_details>Consecutive patients aged 18-75 fulfilling Behçet’s disease International Study Group criteria (16) with the presence of active oral ulcers (OU) within the previous year were included. A further requirement was the presence of at least 2 OU accessible to measurement and with a total diameter of at least 4 mm.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>1</title>
          <description>(placebo)0 IU IFN alpha</description>
        </group>
        <group group_id="P2">
          <title>2</title>
          <description>(Veldona)500 IU IFNα bid</description>
        </group>
        <group group_id="P3">
          <title>3</title>
          <description>(Veldona)1000 IU IFNα bid</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1</title>
          <description>(placebo)0 IU IFN alpha</description>
        </group>
        <group group_id="B2">
          <title>2</title>
          <description>(Veldona)500 IU IFNα bid</description>
        </group>
        <group group_id="B3">
          <title>3</title>
          <description>(Veldona)1000 IU IFNα bid</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
            <count group_id="B2" value="31"/>
            <count group_id="B3" value="26"/>
            <count group_id="B4" value="84"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36" spread="8.6"/>
                    <measurement group_id="B2" value="37" spread="10.2"/>
                    <measurement group_id="B3" value="36" spread="9.4"/>
                    <measurement group_id="B4" value="37" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Turkey</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Comparison of Patients Experiencing a Sustained Response for Each Treatment Arm.</title>
        <description>A patient with a 75% or greater decrease in total OU for three visits was considered a “sustained responder”.</description>
        <time_frame>(0-12 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1</title>
            <description>(placebo)0 IU IFN alpha</description>
          </group>
          <group group_id="O2">
            <title>2</title>
            <description>(Veldona)500 IU IFNα bid</description>
          </group>
          <group group_id="O3">
            <title>3</title>
            <description>(Veldona)1000 IU IFNα bid</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Patients Experiencing a Sustained Response for Each Treatment Arm.</title>
          <description>A patient with a 75% or greater decrease in total OU for three visits was considered a “sustained responder”.</description>
          <units>patients with sustained response</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Results were expressed as mean or number. Normal distributed data among the treatment groups were compared by One-way ANOVA test, non-normal distributed data were compared by Kruskal Wallis test, and then Bonferroni post-hoc test was used for multiple comparisons. Differences from baseline within treatment groups were evaluated by repeated measures ANOVA test for normal distributed data, Freidman test for non-normal distributed data.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.404</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Initial Response, Oral Ulcer Sustained Response, Oral Ulcer Recurrence, Time to Recurrence, Pain Associated With Oral Lesions, General Well-Being, Safety</title>
        <time_frame>12 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>1</title>
          <description>(placebo)0 IU IFN alpha</description>
        </group>
        <group group_id="E2">
          <title>2</title>
          <description>(Veldona)500 IU IFNα bid</description>
        </group>
        <group group_id="E3">
          <title>3</title>
          <description>(Veldona)1000 IU IFNα bid</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0"/>
                <counts group_id="E2" subjects_affected="1"/>
                <counts group_id="E3" subjects_affected="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>cervical intraepithelial neoplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2"/>
                <counts group_id="E2" subjects_affected="5"/>
                <counts group_id="E3" subjects_affected="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Hasan Zeytin MD., Ph.D.</name_or_title>
      <organization>Nobel Ilac San ve Tic. A.S.</organization>
      <phone>+90 216 6336012 ext 6012</phone>
      <email>hasan.zeytin@nobel.com.tr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

